慶應義塾

Medicine and Dentistry

1. Esophageal Cancer 100%
2. Esophagectomy 79%
3. Surgery 61%
4. Neoplasm 61%
5. Stomach Cancer 56%
6. Esophageal Squamous Cell Carcinoma 46%
7. Sentinel Node 38%
8. Recurrent Disease 36%
9. Disease 33%
10. Lymph Node Metastasis 32%
11. Overall Survival 31%
12. Malignant Neoplasm 30%
13. Metastatic Carcinoma 30%
14. Colorectal Cancer 28%
15. Liver Transplantation 26%
16. Gastrectomy 25%
17. Rheumatoid Arthritis 24%
18. COVID-19 24%
19. Chemoradiotherapy 22%
20. Retroperitoneal Lymph Node Dissection 20%
21. Sentinel Lymph Node 19%
22. Neoadjuvant Chemotherapy 19%
23. Lymph Node 19%
24. Postoperative Complication 18%
25. Surgeon 18%
26. Hazard Ratio 17%
27. Sentinel-Node Mapping 17%
28. Computer Assisted Tomography 17%
29. Cisplatin 17%
30. Hepatectomy 17%
31. Retrospective Study 16%
32. Endoscopic Surgery 16%
33. Hepatocellular Carcinoma 16%
34. Symptom 15%
35. Breast Cancer 15%
36. Recurrence Free Survival 15%
37. Pancreas Cancer 15%
38. Odds Ratio 15%
39. Pemphigus 14%
40. Systematic Review 13%
41. Prognostic Factor 13%
42. Anastomosis Leakage 13%
43. Fluorouracil 13%
44. Retrospective Cohort Study 13%
45. Magnetic Resonance Imaging 13%
46. Neoadjuvant Therapy 12%
47. Cervical Spine 12%
48. Cancer Surgery 12%
49. Esophagus 12%
50. Infection 12%
51. Diagnosis 12%
52. Meta-Analysis 12%
53. Surgical Infection 11%
54. Multivariate Analysis 11%
55. Survival Rate 11%
56. Adverse Event 10%
57. Methotrexate 10%
58. Cholangiocarcinoma 10%
59. Clinical Significance 10%
60. Laparoscopic Surgery 10%
61. Docetaxel 9%
62. Ossification 9%
63. Disease Activity 9%
64. Quality of Life 9%
65. Biopsy 9%
66. Nivolumab 9%
67. Surgical Technique 9%
68. Clinical Trial 9%
69. Systemic Lupus Erythematosus 8%
70. Tocilizumab 8%
71. Pancreas Adenocarcinoma 8%
72. Posterior Longitudinal Ligament 8%
73. Laminoplasty 8%
74. Laparoscopy 8%
75. Pancreaticoduodenectomy 8%
76. Carcinoma 8%
77. Bleeding 8%
78. Injury 8%
79. Radiation Therapy 8%
80. Cohort Analysis 8%
81. Cancer Cell 8%
82. Desmoglein 1 7%
83. Knee 7%
84. Autoantibodies 7%
85. Lymphocyte 7%
86. Esophagus Carcinoma 7%
87. Long Term Survival 7%
88. Body Mass Index 7%
89. Cancer 7%
90. Surgical Mortality 7%
91. Colon Cancer 7%
92. Fibrinogen 7%
93. Primary Tumor 7%
94. Predictive Factor 7%
95. Pemphigus vulgaris 7%
96. Cervical Myelopathy 7%
97. Elderly Patient 7%
98. Randomized Controlled Trial 7%
99. C Reactive Protein 6%
100. Biological Marker 6%

Keyphrases

1. Japan 35%
2. Rheumatoid Arthritis 35%
3. Esophageal Cancer 35%
4. Esophageal Squamous Cell Carcinoma 19%
5. Japanese Patients 18%
6. Methotrexate 16%
7. Light Propagation 15%
8. Overall Survival 13%
9. Sentinel Lymph Node 12%
10. Optical Path Length 12%
11. Esophagectomy 11%
12. Near-infrared 11%
13. Neoadjuvant Chemotherapy 10%
14. Pemphigus Vulgaris 10%
15. Pemphigus 10%
16. Post-esophagectomy 10%
17. Active Rheumatoid Arthritis 10%
18. Brain Activation 9%
19. Lymph Node Metastasis 9%
20. Desmoglein 3 9%
21. Topography Image 9%
22. Head Model 9%
23. Cortex 9%
24. Gastric Cancer 9%
25. Desmoglein 8%
26. Cisplatin 8%
27. Early Gastric Cancer 8%
28. Autoantibodies 8%
29. 5-fluorouracil (5-FU) 8%
30. Confidence Interval 8%
31. Risk Factors 8%
32. Oxyhemoglobin 7%
33. Deoxyhemoglobin 7%
34. Colorectal Cancer 7%
35. Disease Activity 7%
36. Phase II Study 7%
37. Rheumatoid Arthritis Patients 7%
38. Retrospective Cohort Study 7%
39. Thoracoscopic Esophagectomy 7%
40. Wavelength Dependence 7%
41. Tocilizumab 7%
42. Monte Carlo Simulation 7%
43. Systemic Lupus Erythematosus 7%
44. Spatial Resolution 7%
45. Chemotherapy 7%
46. Sensitivity Profile 7%
47. Spatial Sensitivity 7%
48. COVID-19 7%
49. Hazard Ratio 7%
50. DSG3 6%
51. Docetaxel 6%
52. Remission 6%
53. Tumor 6%
54. Sentinel Lymph Node Mapping 6%
55. Lack of Response 6%
56. Postoperative Complications 6%
57. Source-detector 6%
58. Randomized Double-blind 6%
59. Phase II Trial 6%
60. Interleukin-6 6%
61. Adalimumab 6%
62. Monotherapy 6%
63. Prognostic Impact 6%
64. Cortical Tissue 6%
65. Nivolumab 6%
66. Abatacept 6%
67. Pemphigus Foliaceus 6%
68. Chemoradiotherapy 6%
69. Short-term Outcomes 5%
70. Optical Properties 5%
71. Prognostic Significance 5%
72. National Clinical Database 5%
73. Advanced Esophageal Cancer 5%
74. Epidermis 5%
75. Multispectral Image 5%
76. Adult Head 5%
77. Clinical Characteristics 5%
78. Pancreatic Cancer 5%
79. Multispectral Imaging 5%
80. Placebo 5%
81. Cancer Patients 5%
82. Hemoglobin Concentration 5%
83. After Surgery 5%
84. Thoracic Esophageal Cancer 5%
85. Prognostic Factors 5%
86. American College of Rheumatology 5%
87. Topographic Imaging 5%
88. Paraneoplastic Pemphigus 5%